Newsletter - Banner

Breadcrumb

Asset Publisher

Study identifies strategies to reduce breast cancer growth and related skeletal lesions

RI-MUHC team publishes findings in the journal, Bone Research

Early treatment trial of hydroxychloroquine shows no symptomatic benefit for COVID-19 patients

Adult outpatients with mild symptoms of COVID-19 don’t benefit from taking hydroxychloroquine

Sodium found to regulate the biological clock of mice

New study by RI-MUHC researchers first to establish that physiological signals influence circadian rhythms

At the heart of precision medicine

New translational collaboration aims to transform approach to heart muscle disease

Novel gene therapy trial offers hope to patients with rare metabolic disease

Samuel is the first Canadian and the ninth patient worldwide to participate in the second phase of a study using gene therapy to treat Glycogen storage disease type I, otherwise known as GSD.

Call for Applications: Executive Director and Chief Scientific Officer, Research Institute of the McGill University Health Centre (RI-MUHC)

The RI-MUHC is seeking a dynamic and strategic leader to serve as its next Executive Director and Chief Scientific Officer (ED/CSO)

Interdisciplinary Consortium Receives Grant to Develop Next-Generation Cell-Based Cancer Vaccines

Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers

COVID-19 pandemic: Looking back to better tackle future challenges

In two recent studies, RI-MUHC researchers provide useful information for evaluating public health strategies

Canadian researchers work together to develop made-in-Canada COVID-19 testing capacity

The road towards Canadian testing capacity began in Montreal

Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper

A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis

COVID-19 pandemic: the need for privacy and digital contact tracing

RI-MUHC researcher Abhinav Sharma calls for an approach emphasizing voluntary consent

COVID-19 impact on cancer patients: MUHC researchers take part in a multinational study

Published in The Lancet, the study reveals cancer-specific factors associated with increased mortality

Why do some non-smokers get COPD while many heavy smokers don’t?

A new study highlights a strong risk factor for COPD related to lung development

Hydroxychloroquine not effective in preventing the development of COVID-19 when used as post-exposure prophylaxis

A new study suggests that hydroxychloroquine is not effective in preventing the development of COVID-19 in individuals exposed to SARS-CoV-2

Interim Leadership of the Research Institute of the MUHC

The Board of Directors of the RI-MUHC is pleased to announce the appointment of Dr. Miguel N. Burnier, Jr. to the position of Interim Executive Director and Chief Scientific Officer of the RI-MUHC

Made-in-Canada COVID-19 test developed at McGill receives government support

Government support for McGill and RI-MUHC team in COVID-19 testing

COVID-19 Q&A: Tina Montreuil on helping children cope with anxiety

“It is not only what you say that matters, but what you do”

The RI-MUHC receives and tests the first UV-Disinfection robot in Canada

Novel robotics technology could potentially reduce healthcare-associated infections

International consortium investigates overactive immune cells as cause of COVID-19 deaths

New publication links neutrophil infiltration in the lungs of patients to COVID-19 symptoms

See Archive - What's New